Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.
View/
Volume
101
Pagination
e339 - e342
DOI
10.3324/haematol.2015.139667
Issue
Metadata
Show full item recordAuthors
de Haart, SJ; Holthof, L; Noort, WA; Minnema, MC; Emmelot, ME; Aarts-Riemens, T; Doshi, P; Sasser, K; Yuan, H; de Bruijn, J; Martens, AC; van de Donk, NW; Lokhorst, HM; Groen, RW; Mutis, TCollections
Language
Copyright statements
